Huang Ben, Feng Yang, Ni Mengdong, Chen Chen, Cai Guoxiang
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
ANZ J Surg. 2018 Apr;88(4):316-321. doi: 10.1111/ans.13737. Epub 2016 Aug 31.
We aim to compare the prognosis between patients with stage IIA and stage IIIA colon cancer.
We analysed patients with stage IIA or stage IIIA colon cancer based on data from the US Surveillance, Epidemiology, and End Results (SEER) database. Survival data were generated as Kaplan-Meier curves and were compared by log-rank tests. A multivariate Cox proportional hazards model was used to analyze the risk factors.
In total, 43 379 patients (38 784 stage IIA and 4595 stage IIIA) were included from the SEER database. A Kaplan-Meier analysis showed no significant difference between patients with stage IIA and IIIA colon cancer (P = 0.547). In the subgroup of patients with number of lymph nodes harvested (LNH) ≥12, a multivariate analysis showed that compared with stage IIA patients, stage IIIA patients were more likely to have a poorer cancer-specific survival (CSS) (hazard ratio (HR) 1.252, 95% confidence interval (CI) 1.095-1.431, P = 0.001). In the subgroup of patients with LNH <12, a multivariate analysis showed that compared with stage IIA patients, stage IIIA patients were more likely to have a better CSS (HR 0.820, 95% CI 0.731-0.919, P = 0.001).
Patients with stage IIA colon cancer had a CSS comparable with that of patients with stage IIIA disease. When adequate lymph nodes were retrieved (LNH ≥12), stage IIA patients had a greater CSS than stage IIIA patients. On the contrary, when inadequate lymph nodes were retrieved (LNH <12), stage IIA patients had a poorer CSS than stage IIIA patients.
我们旨在比较IIA期和IIIA期结肠癌患者的预后。
我们基于美国监测、流行病学和最终结果(SEER)数据库的数据,分析了IIA期或IIIA期结肠癌患者。生存数据以Kaplan-Meier曲线生成,并通过对数秩检验进行比较。采用多变量Cox比例风险模型分析危险因素。
SEER数据库共纳入43379例患者(38784例IIA期和4595例IIIA期)。Kaplan-Meier分析显示,IIA期和IIIA期结肠癌患者之间无显著差异(P = 0.547)。在淋巴结清扫数量(LNH)≥12的患者亚组中,多变量分析显示,与IIA期患者相比,IIIA期患者的癌症特异性生存(CSS)更差的可能性更大(风险比[HR] 1.252,95%置信区间[CI] 1.095 - 1.431,P = 0.001)。在LNH < 12的患者亚组中,多变量分析显示,与IIA期患者相比,IIIA期患者的CSS更好的可能性更大(HR 0.820,95% CI 0.731 - 0.919,P = 0.001)。
IIA期结肠癌患者的CSS与IIIA期疾病患者相当。当获取足够数量的淋巴结(LNH≥12)时,IIA期患者的CSS优于IIIA期患者。相反,当获取的淋巴结数量不足(LNH < 12)时,IIA期患者的CSS比IIIA期患者更差。